Michael Newman

Michael Newman

70 år
Health Technology
Consumer Services

Profil

Michael James Newman was the founder of Decoy Biosystems, Inc., founded in 2013, where the titles held included President, CEO, CFO, Secretary & Director from 2013 to 2021.
Dr. Newman is the founder of Indaptus Therapeutics, Inc., founded in 2021, holding the title of Chief Scientific Officer since 2021.
Former jobs include Executive Director-Oncology at Novartis Pharmaceuticals Corp.
from 1992 to 1997, Senior Associate Director at Sandoz Pharmaceuticals Corp., Director & Chief Scientific Officer at Intec Pharma Ltd., Executive Vice President-Oncology at Huyabio International LLC, Faculty at Brandeis University from 1984 to 1987, Executive Vice President-Oncology at Ontogen Corp., Executive Vice President-Research & Development at Vaxiion Therapeutics LLC, and Chief Scientific Officer & Vice President-Research at Dihedron Corp.
Education includes undergraduate studies at the University of California San Diego and a doctorate from Harvard Medical School.

Aktiva positioner av Michael Newman

FöretagPositionStart
INDAPTUS THERAPEUTICS, INC. Grundare 2021-02-24

Tidigare kända positioner av Michael Newman

FöretagPositionSlut
Verkställande Direktör 2021-08-01
Företagsledare/Principal 1997-01-01
Företagsledare/Principal 1987-01-01
Teknisk/Vetenskaplig/F&U Direktör -
Företagsledare/Principal -
Se detaljerna i Michael Newmans erfarenhet

Michael Newmans utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

75

Första gradens relationer

12

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag12

Health Technology

Consumer Services

Consumer Services

Health Technology

Ontogen Corp.

Sandoz Pharmaceuticals Corp.

Health Technology

Consumer Services

Dihedron Corp.

Health Technology

Health Technology

Health Technology

  1. Börsen
  2. Insiders
  3. Michael Newman
40% rabatt: De bästa verktygen för prenumeranter för att identifiera morgondagens bästa investeringar!
d
:
:
TA DEL AV DET NU